Pharmaceutical Technology
DECEMBER 16, 2022
GnRH antagonists have an improved safety and efficacy profile compared to the marketed GnRH agonists, which have significant side effects that are unappealing to patients. This therapy is currently in Phase II development and is expected to launch in the US and 5EU in 2027 and 2028, respectively. of 7MM sales.
pharmaphorum
JULY 26, 2022
There was also continued decline for Tecfidera, which have not been offset by follow-up Vumerity (diroximel fumarate), which has fewer side effects. It had expected the drug would not face biosimilar competition in Europe until at least 2027. Tecfidera’s decline has made Tysabri Biogen’s top-selling drug.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Medico Reach
FEBRUARY 8, 2023
The Emergence of the Pharmacovigilance Market Medicines and vaccines often have unwanted and severe side effects. Such results call for stringent vigilance on the medicines quality and after-effects, nudging the emergence of the pharmacovigilance market. billion by 2027. billion in 2022 and will expand at a CAGR of 10.3%
Pharmaceutical Technology
NOVEMBER 30, 2022
In the past, obesity medications were often dismissed due to insufficient efficacy data and the fact that they were associated with a high occurrence of side effects. Over the past few years, there has been a boom in anti-obesity drug development, with major companies achieving substantial sales in the field. million in Q3.
Pharmaceutical Technology
NOVEMBER 30, 2022
In the past, obesity medications were often dismissed due to insufficient efficacy data and the fact that they were associated with a high occurrence of side effects. Over the past few years, there has been a boom in anti-obesity drug development, with major companies achieving substantial sales in the field. million in Q3.
Expert insights. Personalized for you.
59 
Let's personalize your content